Ten years after the Mediator case began, Servier has changed its face. If its image remains marked by the 1,500 deaths caused by this drug, the French laboratory has been profoundly transformed. However, it will still take time to turn the page. While the trial opened on September 23 before the Paris Criminal Court, the indictment of the prosecution is scheduled for late April. The judgment could then be put under advisement. "Patients have the right to the truth," insists the director general of the laboratory, Olivier Laureau.
Read also: Our file on the Mediator case: all you need to know about this extraordinary trial
If some feared for his survival, Servier managed to weather the legal and media storm. It recorded last year (financial year ended September 30, 2019) a turnover of 4.6 billion euros, an increase of 10.5%, divided between its core drug activity (70% of sales) and generics (30%). Its operating profit was however weighed down (-34%) by a series of acquisitions and investments. The
This article is for subscribers only. You still have 73% to discover.
Subscribe: € 1 for 2 months
cancellable at any time
Enter your emailAlready subscribed? Login